PRME

3.5657.16%
DP

David P. Schenkein

Independent Director

Dr. David P. Schenkein, M.D. Ph.D. serves as a Director of Aera Therapeutics. He serves as Director at Delphia Therapeutics, Inc. He serves as Director at Regeneron Pharmaceuticals, Inc. since September 8, 2023. He has been an Independent Director at Prime Medicine, Inc since September 2019. Dr. Schenkein was a Member of Scientific Advisory Board at BeiGene Ltd. since April 2021 and serves as its Member of Scientific Advisory Board since 2025. Dr. Schenkein serves as Board Observer of Encoded Therapeutics, Inc. He had been a Member of Scientific Advisory Board at Monte Rosa Therapeutics, Inc. until December 2023. He serves as a Supervisory Board Member at Leyden Laboratories B.V. He was a Board Advisor and was Board Observer at National Resilience, Inc. He serves as Member of Scientific Advisory Board at Foghorn Therapeutics Inc. Dr. Schenkein serves as General Partner at GV Management Company, LLC since February 11, 2019. He joined GV as a co-head of its life sciences investment branch. He is an adjunct attending physician in hematology at Tufts Medical Center. He served as Chief Executive Officer and President of Agios Pharmaceuticals, Inc. since Leyden Laboratories B.V. from August 2009 to January 2019. He serves on the board of Leyden Laboratories B.V. He served on the board of directors of Leyden Labs, Inc and Treeline Biosciences. He served as Executive Chairman of Agios Pharmaceuticals, Inc. from February 2020 to August 08, 2022 and served as its Executive Chairman from February 2019 to February 2020. He served as a Venture Partner at Arch Venture Partners, L.P. Dr. Schenkein served as a Senior Vice President of Clinical Hematology & Oncology at Genentech, Inc. from March 2006 to July 2009. He served as Vice President of Clinical Hematology & Oncology at Genentech Inc. since May 11, 2006 and served as its Vice President since February 2006. He served as Senior Vice President of Clinical Research of Millennium Pharmaceuticals, Inc. since March 14, 2005. He had led a clinical team that worked in collaboration across Millennium, with academia, advocacy groups and other external parties to gain FDA and EMEA approval for VELCADE(R) (bortezomib) for Injection, the first treatment to be approved for patients with multiple myeloma in more than a decade. He was also been pivotal in driving the strategy for exploring VELCADE(R) (bortezomib) for Injection in other indications. Similarly, he ensured the effective management of Millennium Pharmaceuticals, Inc.'s clinical development program for the oncology pipeline. He has been Independent Director of Agios Pharmaceuticals, Inc. since August 2009. He had been a Director of bluebird bio, Inc. from April 2013 to January 09, 2021. He has been an Independent Director of Biotechnology Industry Organization since 2012. He has been Independent Director of Denali Therapeutics Inc. since April 2015. He serves as general partner of Google Ventures life science team. He served as a Member of Scientific Advisory Board at BeOne Medicines Ltd. (formerly known as BeiGene, Ltd.) He served as Blueprint Medicines Corporation since February 2013. He served as an Independent Director of Foundation Medicine, Inc. since 2010 until June 20, 2017. Prior to Millennium, Dr. Schenkein served as a Director of Cancer Center of Tufts-lymphoma and other hematologic malignancies. He is an Associate Professor of Medicine at Tufts University School of Medicine. He has been a Medical Oncologist and Hematologist. He served as an adjunct Clinical Professor of Medicine at the Stanford University Cancer Center. He holds an attending physician appointment in Hematology Oncology at the Tufts-New England Medical Center in Boston. Dr. Schenkein holds a Bachelor of Arts in Chemistry at Wesleyan University and a Medical Degree (M.D.) from State University of New York Upstate Medical School in Syracuse.

Positions